Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: A randomised controlled study
| Autor: | Tetsuo Taguchi, Tatsuhei Kondo, Shigeru Fujimoto, Tadashi Kimura, Hisashi Furue, Kunzo Orita, Nobuya Ogawa, Koichi Yoshida |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
Oncology medicine.medical_specialty Multivariate analysis Sizofiran medicine.medical_treatment Injections Intramuscular law.invention chemistry.chemical_compound Adjuvants Immunologic Randomized controlled trial Stomach Neoplasms law Internal medicine medicine Humans Aged business.industry Cancer Middle Aged Prognosis medicine.disease Clinical trial chemistry Multivariate Analysis Curative surgery Female Primary tumour size business Adjuvant |
| Zdroj: | European Journal of Cancer and Clinical Oncology. 27:1114-1118 |
| ISSN: | 0277-5379 |
| Popis: | Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran (SPG), an extract from the culture broth of Schizophyllum commune Fries, was prescribed randomly for 386 Japanese patients with resectable gastric cancer. Although the overall survival probability for 5 years did not differ between the SPG and control groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the sizofiran-administered patients was better than in the controls. In the multivariate analysis, four of six prognostic factors correlated with the prognosis of the 264 patients who underwent curative surgery, that is, nodal involvement (chi 2 = 21.426, P = less than 0.0001), age distribution (chi 2 = 9.262, P = 0.010), sizofiran administration (chi 2 = 6.507, P = 0.011), and primary tumour size (chi 2 = 9.345, P = 0.025). Thus, patients with a curatively resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|